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This procedure, however, can be quite invasive, with the potential for morbidity. Moreover, autologous bone grafting is not suitable for every patient, as it is dependent on the availability and quality of the host's bone. [3] [4] [5] [6] Thus, in the field of bone research, tissue-engineering modalities are increasingly focused on enhancement of osteogenesis in bone defects above a critical size. To date, many different types of bone graft substitute materials have been explored, including osteoconductive scaffolds, osteoprogenitor cells, and/ or osteoinductive factors. 7 Recombinant human bone morphogenetic protein-2 (INFUSE; Medtronic Sofamor Danek, Minneapolis, Minn.) is the most common osteogenic cytokine for orthopedic application. However, the supraphysiologic dosages of recombinant human bone morphogenetic protein-2 required for bone healing in humans (e.g., 1.5 mg/ml) have been linked to an increase in adverse side effects, including native bone resorption, heterotopic bone formation, soft-tissue swelling, dysphagia, and airway compromise. 8 Thus, despite the brisk bone formation induced by recombinant human bone morphogenetic protein-2 in humans, a search for safer alternative growth and differentiation factors is warranted.
In adult tissue, the hedgehog signaling pathway is a critical moderator of cell differentiation and demonstrates both pro-osteogenic and antiadipogenic properties in mesenchymal stem cells. 9, 10 In the context of postnatal osteogenesis or bone healing, hedgehog expression is first detected in the chondrocytes during early cartilage condensation and is later expressed primarily in the transitional region from proliferating to hypertrophic chondrocytes. [11] [12] [13] It indirectly suppresses hypertrophic differentiation and is later involved in ossification. 12 Hedgehog ligands signal through a mechanism involving two transmembrane proteins: Patched (Ptc) and Smoothened (Smo). The initial phase of the hedgehog signaling activation is characterized by the binding of hedgehog proteins to a transmembrane receptor known as Ptc. In the absence of hedgehog ligand, Ptc suppresses Smo activity; binding of hedgehog to Patched releases Smoothened, which then transmits the intracellular signaling cascade, resulting in increased transcription of downstream genes including glioblastoma gene products (Gli) transcription activators instead of transcriptional repressors. 14 Smoothened agonist (SAG) is a small molecule that activates hedgehog signaling by high-throughput screening of chemical libraries, together with purmorphamine. [15] [16] [17] [18] [19] SAG induces osteoblast markers in mesenchymal stem cells 20 and calvarial osteoblasts, 21 but results in either a modest 21 or partial 20 induction of osteoblastogenic programming. Therefore, SAG alone may be insufficient for promoting bone healing of a defect of critical size.
Nel-like protein-1 (NELL-1) is a differentiation factor that also plays a role in osteogenesis, discovered initially in patients with nonsyndromic unilateral coronal synostosis. 22 Research findings showed that an overexpression of Nell-1 gene in mice was linked to craniosynostosis-like phenotypes, calvarial bone overgrowth, and increased osteoblastic differentiation, whereas Nell-1 gene deficiency restricted bone growth. 23 Mice with nonsense mutations in the Nell-1 gene have craniofacial, spine, and long bone anomalies that ultimately led to perinatal death. 24, 25 NELL-1 also appears to selectively promote osteochondrogenic lineage differentiation in mesenchymal stem cells, both in vitro and in vivo. [26] [27] [28] [29] [30] Previously, we observed evidence of a combinatorial effect between hedgehog signaling and NELL-1 signaling in driving osteogenic differentiation of mesenchymal stem cells in vitro. 31 Moreover, chemical abrogation of hedgehog signaling impaired NELL-1-induced osteogenesis. 31 However, in vitro studies alone cannot replicate the complex, local microenvironment of the bone defect. To create a better predictive model of human efficacy, the present study sought to extend our findings by manipulating NELL-1 and hedgehog signaling in a mouse calvarial bone defect model.
MateRials anD MethoDs

Preparation of scaffolds
Hydroxyapatite-coated poly(lactic-co-glycolic acid) was used as the scaffold or carrier for protein delivery, which was fabricated from 85/15 poly(lactic-co-glycolic acid) (inherent viscosity, 0.61 dl/g; Birmingham Polymers, Pelham, Ala.; http://www.durect.com) by solvent casting and a particulate leaching process. Briefly mixed poly(lactic-co-glycolic acid)/chloroform was compressed into thin sheets in a polytetrafluoroethylene mold to build a disk-shaped construct (diameter, 4 mm). After freeze-drying overnight, sucrose was dissolved from the scaffolds by immersion in three changes of double-distilled water. The scaffolds were then relocated from the polytetrafluoroethylene plate for disinfection and drying. Sequentially dissolved calcium chloride, magnesium chloride hexahydrate, sodium bicarbonate, and potassium hydrogen phosphate trihydrate in double-distilled water, also known as simulated body fluid solution, was prepared for apatite coating. The solution's pH was lowered to 6 by adding 1 M hydrochloric acid to enhance the solubility. Sodium sulfate, potassium chloride, and sodium chloride were added to adjust the final pH to 6.5 (simulated body fluid 1). Simulated body fluid free of magnesium ion and bicarbonate (simulated body fluid 2) was formed by adding calcium chloride and potassium hydrogen phosphate trihydrate in double-distilled water with pH adjusted to 6. Potassium chloride and sodium chloride were added to obtain a final pH of 6.8. All sterile solutions were filtered through a 0.22-mm polyether sulfone membrane (Nalgene). The poly(lactic-co-glycolic acid) scaffolds were incubated in simulated body fluid 1 for 12 hours and then removed and placed in the simulated body fluid 2 solution for another 12 hours at 37°C with gentle agitation. Coated scaffolds were disinfected by soaking in 70% ethanol for 30 minutes, rinsing three times in double-distilled water, and drying under a laminar flow hood.
Four groups of scaffolds were coated by adsorption with 0.01% dimethylsulfoxide (control) (n = 6 mice), SAG (1.0 mM) (n = 7 mice), NELL-1 (600 μg/ml) (n = 7 mice), or SAG plus NELL-1 (1.0 mM and 600 μg/ml, respectively) (n = 7 mice) 24 hours before surgery. To control for any potential effects of the dimethylsulfoxide within SAG solution, all scaffolds were supplemented with equivalent concentration of dimethylsulfoxide solution. SAG was purchased from EMD Millipore Co. (Billerica, Mass.), and recombinant human NELL-1 was purified by Aragen Bioscience, Inc. (Morgan Hill, Calif.). Doses of SAG and NELL-1 were based on previously published studies. 32, 33 animal Models and surgical Procedure
Ten-week-old CD-1 mixed-gender mice (n = 27) weighing 28 to 35 g were obtained from Charles River Laboratories (Wilmington, Mass.) and were used for the experimentation according to the approved protocol of the Chancellor's Animal Research Committee of the University of California, Los Angeles. Preoperatively, buprenorphine (0.05 mg/kg) was injected subcutaneously for analgesic purposes. The mice were anesthetized with isoflurane (4 to 5% induction, 1.5 to 2.5% maintenance). Hair was shaved and skin was disinfected with three alternating povidone-iodine/ alcohol scrubs. Bland ophthalmic ointment was applied to the eyes to prevent corneal desiccation. A heating pad (maintained at 37°C) was used in the operating field. Under surgical magnifying loupes, a dermal incision was made from the nasal bone to the middle sagittal crest, exposing the right parietal bone by removal of the pericranium. A nonhealing, critical-size (4 mm in diameter), full-thickness calvarial defect was created in the right parietal bone using a dental surgical drilling unit with a trephine under saline irrigation, avoiding damage to the bone sutures and the underlying dura. Carefully, the scaffold was placed within the defect in a shift-minimizing position. [see 
in Vivo live Micro-Computed tomographic imaging and analyses
Animals under general anesthesia (isoflurane, 4 to 5% induction and 1.5 to 2.5% maintenance) were scanned at 0, 4, and 8 weeks after surgery using a high-resolution micro-computed tomography device (SkyScan 1176; Bruker MicroCT N.V., Kontich, Belgium) at a resolution of 18 μm to evaluate healing of the bone defect. Scan settings were as follows: aluminum filter, 0.5 mm; voltage, 50 kVp; anode current, 500 mA; exposure time, 250 msec; frame averaging, 2; and rotation step, 0.4 degree. After scanning, animals were observed for recovery before return to the animal facility.
Three-dimensional images were constructed by implementing the Feldkamp algorithm, and morphometric analyses were performed with SkyScan 1172 CT-Analyzer software. A disk-shaped region of interest was defined with a 4-mm diameter and 1-mm height to include all new bone formation in the calvarial defect site. (see The presence of 4-mm bone defects was confirmed by analyzing immediate postoperative micro-computed tomographic scans (which were analyzed to make sure there were minimal differences in the initial bone defect size). Then, the amount of bone formation was analyzed and quantified in three different ways by comparing scans to identical images taken postoperatively. First, bone volume density [bone volume/tissue volume (percent)] and bone mineral density (in grams per cubic centimeter) were calculated from binary x-ray images. Second, bone thickness (in millimeters) was analyzed to detect new bone formation within the defect area. By using the maximum intensity projection tool of ImageJ software (National Institutes of Health, Bethesda, Md.) to reproject the three-dimensional volume of interest onto a two-dimensional plane, a 4-mm region of interest was centered on the calvarial defect. 34 Next, by using the marching cubes method to generate three-dimensionally-rendered models for visualization of analyzed regions, the extent of newly formed bone within the calvarial defect was scored. The bone healing score scale was applied to grade the quality of calvarial defect healing by three blinded observers according to previously determined methodologies. 35 The score scale consisted of the following designations: 0 = no bone formation, 1 = few bony spicules dispersed through defect, 2 = bony bridging only at defect borders, 3 = bony bridging over partial length of defect, and 4 = bony bridging entire span of defect at longest point.
harvest and histologic analysis
Animals were killed for histologic evaluation 8 weeks after surgery by slow carbon dioxide (20 to 30 percent per minute) asphyxiation and cervical dislocation as a confirmatory method. Calvaria were harvested, paraformaldehyde fixed, 19% ethylenediaminetetraacetic acid decalcified, paraffin embedded, and sectioned at 5-μm thickness. Three slides were used per animal, and all animals were evaluated for histomorphometric analysis.
Hematoxylin and eosin, Masson trichrome, and picrosirius red section staining were performed using the decalcified samples. Images of stained coronal cross-sections of each sample at the mid-calvarial defect area were obtained under light microscopy and analyzed histomorphometrically using Adobe Photoshop software (Adobe Systems, Inc., San Jose, Calif.) under the following parameters: bone area (number of pixels per high-power field), fractional bone area (bone as a fraction of tissue area), blood vessel number (number of blood vessels per high-power field), and fractional blood vessel area (number of pixels as a fraction of tissue area). Six to 12 adjacent high-power fields on each image were analyzed to encompass the entire defect area of each sample on a representative section.
Immunohistochemical staining was performed, and additional sections were incubated with the following primary antibodies: anti-CD31 (1:50; Abcam, Cambridge, Mass.), anti-Patched1 (Ptc1) (1:1000; Abcam), and anti-Gli1 (1:500; Abcam). The following secondary antibodies were used: biotinylated anti-rabbit or anti-goat immunoglobulin G secondary antibody (1:200; Vector Laboratories, Inc., Burlingame, Calif.). The paraffin slices were deparaffinized, dehydrated, rinsed, and incubated with 3% hydrogen peroxide for 20 minutes using the ABC (Vector Laboratories) method. Heat-induced epitope retrieval was performed for 20 minutes with steam, using 10 mM sodium citrate buffer, pH 6.0. All sections were then blocked with 5% normal goat serum (Vector Laboratories) in phosphate-buffered saline for 1 hour. Primary antibodies were added to each section at their respective dilutions and incubated at 37°C for 1 hour and then overnight at 4°C. Positive immunoreactivity was detected following ABC complex (PK-6100, Vectastain Elite ABC Kit; Vector Laboratories) incubation and development with diaminobenzidine (Vector Laboratories). Mayer hematoxylin (Abcam) was used as a nuclear counterstain and slides were mounted using an aqueous media (Faramount; Dako, Carpinteria, Calif.).
statistical analysis
Statistical analysis was performed using IBM SPSS for Windows Version 18.0 (IBM Corp., Armonk, N.Y.). All data are shown as medians ± ranges. Statistical significance between two groups was evaluated by the Mann-Whitney U test. Kruskal-Wallis test with post hoc tests of Bonferroni was used in multiple group comparisons. In addition, intraclass correlation coefficient was analyzed to determine the interrater and intrarater reliability of the subjective data from the three independent observers' scores. Statistical significance was set at p < 0.05.
Results
Radiographic evaluation of Bone Regeneration
Micro-computed tomographic imaging and analysis was performed at 0, 4, and 8 weeks after surgery, for serial follow-up of bone formation. Minimal variation of calvarial defect size was determined by the micro-computed tomographic images and analysis at time 0. [see Figure, supplemental Digital Content 3, which shows an in vivo micro-computed tomographic image of a calvarial defect at week 0. To evaluate any differences in the initial calvarial defect size, in vivo microcomputed tomographic images and analyses were examined at week 0 (just after surgery). (Above) Images and (below) quantification of defect diameter indicate minimal variation in the initial bone injury size. Box plot shows the median along with the first and third quartiles. Error bar indicates data range from minimum to maximum, http:// links.lww.com/PRS/C163.] Postoperative results showed that all parameters related to bone formation increased gradually over time (Fig. 1) . As shown in the whole-skull reconstructions (Fig. 1,  above) and quantitative three-dimensional analyses of osteogenesis in micro-computed tomographic images (Fig. 1, below, left and below, center) , SAG treatment induced more osteogenesis mainly at the Next, bone healing scores were obtained by three blinded observers (Fig. 1, center, right and  below, right) . Substantiating our findings by microcomputed tomographic reconstruction, the induction of bone healing was observed with SAG alone, NELL-1 alone, and both SAG plus NELL-1 in combination. The SAG plus NELL-1 treatment group showed a significantly higher bone healing score than all other groups, which was appreciated best at the 8-week time point. Intraclass correlation coefficients for interobserver agreement were 93.9 percent and 95.1 percent at the 4-and 8-week time points, respectively. Intraclass correlation coefficients for intrarater reliability of raters 1, 2, and 3 ranged from 94.1 to 98.4 percent.
Next, a bone thickness distribution map of the newly formed bone was analyzed based on microcomputed tomographic images (Fig. 2) . In this representation, the thickest bone appears blue and the thinnest appears red (Fig. 2, above) . Consistent with our previous findings, the combination SAG plus NELL-1 treatment showed maximal new bone thickness. Next, quantitative analyses of bone thickness were performed (Fig. 2, below) . Either SAG or NELL-1 treatment alone led to an increase in bone thickness, although NELL-1 treatment did not reach statistical significance. The combination treatment SAG plus NELL-1 led to increased bone thickness compared with either treatment alone.
histologic evaluation of Bone Regeneration
Radiographic findings were confirmed qualitatively by histologic analysis (Fig. 3) . Hematoxylin and eosin staining demonstrated that control-treated samples showed a precipitous cutoff between the edge of the native parietal bone and adjacent fibrous tissue (Fig. 3, above) . The fibrous tissue of the nonossified defect was intermixed with residual scaffold material (Fig. 3 , above, right) and associated multinucleated foreign body giant cells (Fig. 3, above, right) . In contrast, SAG plus NELL-1 treatment resulted in a significant increase in new woven and lamellar bone formation, which was most prominent at the defect edge but was also scattered throughout the implantation site (Fig. 3, below) . Each treatment alone showed a similar increase in new bone formation, although the quantity of new bone was not as robust (Fig. 3, second and third rows) . Additional histologic stains were used to highlight the bone matrix. [see Figure, Next, histomorphometric analysis of the defect site was performed, examining either bone area or percentage bone area (Fig. 4) . Confirming our micro-computed tomographic observations, either SAG or NELL-1 when applied alone resulted in a significant increase in both parameters of bone formation. Likewise and in agreement with micro-computed tomographic findings, the combination therapy SAG plus NELL-1 resulted in a significant increase in bone area and bone area/tissue area, in comparison with either component alone.
As mentioned, SAG exerts its pro-osteogenic effect by means of hedgehog signaling activation. To confirm that the applied SAG induced hedgehog signaling activity within the defect site, we used immunohistochemical detection for two reporters for hedgehog signaling activity, Ptc1 and Gli1. [see Figure, supplemental Digital Content 6, which shows a hedgehog signaling analysis. (Above) Representative immunohistochemical staining for Gli1, highlighting the presence of increased hedgehog signaling activity among SAG-treated bone defects. (Below) Representative immunohistochemical staining for Ptc1, highlighting the presence of increased hedgehog-signaling activity among SAG-treated bone defects. Arrowheads indicate representative positive staining among stromal or bone-lining cells. Scale bar = 50 μm, http://links.lww.com/PRS/ C166.] Hedgehog signaling activity increases expression of Ptc1, which results in a negative feedback loop on hedgehog signaling activity. Gli1 (one of three Gli family members involved in hedgehog signaling activity) is the main positive regulator of hedgehog signaling, whose expression is also regulated by hedgehog signaling activity. Results indicated that control-treated defects showed scattered and low expression of either Gli1 or Ptc1. In contrast, a significant increase in Gli1 and Ptc1 immunoreactive cells was observed among SAG-treated defects, both in stromal cells and in bone-lining cells. 
Plastic and Reconstructive Surgery • June 2017
Finally, we observed by hematoxylin and eosin staining a qualitative increase in neovascularization of the defect site among each treatment condition in comparison with control. We sought to confirm these differences by both immunohistochemical staining for CD31 and histomorphometric quantification of blood vessels within the defect site. [see Figure, 
DisCussion
Combination therapies could have potential for greater efficacy compared with monotherapy because of the synergistic effects of the therapeutics involved. [36] [37] [38] [39] Researchers have previously reported that SAG, together with other materials, improves osteogenic differentiation and bone formation. 31, 40, 41 For example, Maeda et al. reported successful bone healing by the combinatorial use of SAG and helioxanthin derivative without cell transplantation. 32 Also, Kanke et al. used various small molecule inducers, such as SAG and helioxanthin derivative, under serum-free and feederfree conditions to create a stepwise differentiation protocol for osteoblast differentiation from pluripotent stem cells. 42 In this in vivo study, we used small molecule SAG together with NELL-1 protein to enhance bone healing in a critical-size defect model.
Despite having dissimilar pathways, hedgehog and NELL-1 have quite similar effects on progenitor cells/mesenchymal stem cells, including proosteogenic and antiadipocytic properties. These effects on mesenchymal stem cell differentiation are quite dissimilar to other well-studied pathways such as bone morphogenetic protein signaling and insulin-like growth factor signaling. 43 Bone morphogenetic proteins 2 and 7 are already available for clinical use in the orthopedic setting. 44, 45 However, it should be noted that although the majority of bone morphogenetic proteins promote osteogenic commitment in mesenchymal stem cells, 46, 47 bone morphogenetic proteins also demonstrate proadipogenic effects. 48, 49 Similarly, insulin-like growth factor signaling demonstrates dual pro-osteogenic and proadipogenic effects depending on the dose, cell type, and cell culture conditions. 50, 51 In contrast to the bone morphogenetic protein and insulin-like growth factor signaling pathways, our prior examination of hedgehog and NELL-1 signaling showed enhanced osteogenic differentiation and decreased adipogenesis. 41 Therefore, up-regulating hedgehog signaling by SAG would have beneficial effects in bone healing by suppressing adipogenic fate specification and actively promoting bone formation.
NELL-1 is a novel osteoinductive protein that has the potential to directly induce mesenchymal stem cell proliferation and stimulate osteogenic differentiation principally by means of the induction of osteogenic programming. 52 Specifically, NELL-1 can activate the Wnt/β-catenin signaling pathway through binding to integrin β1, 53 Runt-related transcription factor-2 activity and phosphorylation, 54 and mitogen-activated protein kinases signaling. 55 Interestingly, we recently reported that NELL-1 inhibits adipogenic differentiation of 3T3-L1 preadipocytes and mesenchymal stem cells by means of inhibition of the major adipogenic transcription factors, peroxisome proliferator-activated receptor-γ and CCAAT/ Plastic and Reconstructive Surgery • June 2017 enhancer-binding protein. 56 We speculate that this antiadipogenic effect of NELL-1 might be associated with activation of hedgehog signaling. 10 Our previous publication also revealed the similarities in the phenotypes in cranial sutures between hedgehog signaling and NELL-1 genedeficient mice. 56 Loss-of-function experiments of these showed that the role of hedgehog signaling in intramembranous bone ossification may overlap with that of NELL-1 signaling. Juxtaposition of mice with a defect in hedgehog signaling 57 and mice with a defect in NELL-1 25 demonstrated similar decreases of thickness, growth, and extent of mineralization in cranial bones. However, the exact combinatorial or synergistic mechanisms between SAG and NELL-1 are still unclear, and further studies focusing on the molecular intersection of these two pathways is warranted.
An important limitation to this study is the use of recombinant NELL-1 protein rather than a second small molecule. Small molecules have several substantial advantages over their larger counterparts. [58] [59] [60] [61] [62] [63] [64] First, small-molecule medications are often available for oral administration, an interesting method of delivery for future studies. Second, in general, small molecules do not elicit the unwanted immune responses. 65 Third, the bioactivity of small-molecule compounds is not vitally dependent on higher order structural integrity. 62, 66 In contrast, prior studies have suggested that assembly of NELL-1 into homo-oligomeric structures is at least partially required for its bioactive effects. 67 Fourth, the cost of manufacturing and risk of contamination can be considerably diminished by using small molecules. 62 Unfortunately, no known small molecule has yet been developed as an agonist for NELL-1 signaling.
